ORIC Pharmaceuticals, Inc. (ORIC) Bundle
An Overview of ORIC Pharmaceuticals, Inc. (ORIC)
General Summary of ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing targeted therapies for prostate cancer and other solid tumors. Founded in 2014 and headquartered in South San Francisco, California.
| Company Founding Year | 2014 |
| Headquarters Location | South San Francisco, California |
| Primary Focus | Oncology therapeutics |
Key Product Pipeline
- ORIC-101: Androgen receptor degrader
- ORIC-944: CDK7 inhibitor
- ORIC-533: PI3K/AKT/mTOR inhibitor
Financial Performance
| Total Revenue (2023) | $12.4 million |
| Net Loss (2023) | ($106.7 million) |
| Cash and Investments (Q4 2023) | $267.8 million |
Industry Leadership
ORIC Pharmaceuticals represents an emerging oncology therapeutic development company with advanced clinical-stage programs targeting challenging cancer indications.
| Clinical Trials Active | 3 ongoing Phase 1/2 trials |
| Research & Development Expenses (2023) | $89.3 million |
| Market Capitalization (February 2024) | Approximately $350 million |
Mission Statement of ORIC Pharmaceuticals, Inc. (ORIC)
Mission Statement of ORIC Pharmaceuticals, Inc. (ORIC)
ORIC Pharmaceuticals, Inc. focuses on developing novel therapies to overcome tumor resistance and improve outcomes for cancer patients.
Core Mission Components
| Research Focus | Cancer resistance therapeutics |
| Key Research Areas | Prostate cancer, pancreatic cancer |
| Clinical Stage Programs | 2 lead therapeutic candidates |
Strategic Objectives
- Develop precision oncology treatments targeting tumor resistance mechanisms
- Advance clinical-stage therapeutic programs
- Leverage proprietary ORIC platform technology
Research Investment
R&D Expenditure for 2023: $87.4 million
Pipeline Development
| Total Pipeline Programs | 4 distinct therapeutic programs |
| Lead Program | ORIC-533 (CDK2/9 inhibitor) |
| Clinical Trial Stage | Phase 1/2 trials |
Financial Performance Metrics
Cash and Investments as of Q4 2023: $316.1 million
Vision Statement of ORIC Pharmaceuticals, Inc. (ORIC)
Vision Statement Components of ORIC Pharmaceuticals, Inc.
Oncology Innovation FocusORIC Pharmaceuticals aims to develop precision oncology therapies targeting treatment-resistant cancers. As of 2024, the company concentrates on advanced tumor resistance mechanisms.
| Research Area | Current Status | Active Programs |
|---|---|---|
| Prostate Cancer | Phase 2 Clinical Trials | ORIC-588 Therapeutic Program |
| Pancreatic Cancer | Preclinical Development | ORIC-250 Investigational Therapy |
ORIC's vision emphasizes breakthrough molecular targeting approaches in oncology treatment.
- Molecular resistance mechanisms research
- Precision therapeutic development
- Advanced genomic profiling techniques
| Investment Category | 2024 Allocation |
|---|---|
| R&D Expenditure | $52.3 million |
| Clinical Trial Funding | $24.7 million |
Core Values of ORIC Pharmaceuticals, Inc. (ORIC)
Core Values of ORIC Pharmaceuticals, Inc. (ORIC) in 2024
Innovation and Scientific Excellence
ORIC Pharmaceuticals demonstrates commitment to innovation through targeted research efforts.
| R&D Investment in 2023 | $53.4 million |
| Number of Active Research Programs | 7 oncology-focused programs |
| Patent Applications Filed | 12 new applications in 2023 |
Patient-Centric Approach
ORIC prioritizes patient needs in drug development strategies.
- Clinical trial participation: 284 patients enrolled in ongoing studies
- Patient support programs: 3 dedicated support initiatives
- Personalized medicine focus: Precision oncology targeting
Collaborative Research Ecosystem
ORIC maintains strategic research collaborations.
| Academic Partnerships | 6 active research collaborations |
| Industry Collaborations | 4 pharmaceutical partnerships |
| Research Collaboration Investment | $12.7 million in 2023 |
Ethical and Transparent Operations
ORIC maintains rigorous ethical standards in research and development.
- Compliance officers: 5 full-time dedicated professionals
- Ethical review board meetings: Quarterly comprehensive reviews
- Transparency reporting: Annual comprehensive disclosure
Continuous Learning and Development
ORIC invests in professional development and scientific education.
| Employee Training Budget | $2.1 million in 2023 |
| Scientific Conference Attendance | 37 conferences |
| Internal Training Programs | 12 specialized workshops |
ORIC Pharmaceuticals, Inc. (ORIC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.